Collection / CJC-1295 with DAC
CJC-1295 with DAC
CJC-1295 with DAC is a growth-hormone-releasing hormone analogue with a Drug Affinity Complex. Research examines prolonged GH and IGF-1 responses, making it of interest in growth-axis physiology.
Simulation only · No real order or payment.
GHRH analogue with Drug Affinity Complex
Also known as: DAC:GRF
Human trialResearch & handling
Not for human or veterinary use. Storage, handling, identity and purity require verified batch documentation. No dosing or treatment advice is provided.
At a glance
GHRH signalling
The analogue engages the growth-hormone-releasing hormone pathway.
DAC modification
The Drug Affinity Complex distinguishes this long-acting identity from non-DAC materials.
Hormone endpoints
Reviewed human physiology studies measure GH and IGF-1 changes under controlled conditions.
Explore the study context and sources below. For laboratory research only.
Studies & context
The long-acting CJC-1295 molecule was studied in healthy adults for growth-hormone and IGF-I responses.
Human trialTwo randomized studies lasting 28 and 49 days reported sustained increases in GH and IGF-I after the long-acting CJC-1295 intervention.
Study limitations
These are hormone biomarkers, not performance or anti-ageing outcomes.
No serious adverse reactions were reported in these short studies.
Study limitations
This does not establish long-term safety; long-acting data must not be transferred to non-DAC material or blends.
Published research is separate from PEPTIVIA identity, content, purity, sterility and batch documentation. No source-supplier report verifies PEPTIVIA material.